Milestone's options

What cardio play Milestone plans to do with its upsized $55M series C round.

Milestone Pharmaceuticals Inc. turned positive Phase II data for etripamil into an upsized $55 million series C round, which will give the cardiovascular company leeway to expand its core program or in-license a second

Read the full 344 word article

How to gain access

Continue reading with a
two-week free trial.